

# Paul R Harnett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/967089/publications.pdf>

Version: 2024-02-01

100  
papers

4,568  
citations

136950

32  
h-index

106344

65  
g-index

103  
all docs

103  
docs citations

103  
times ranked

7899  
citing authors

#	ARTICLE	IF	CITATIONS
1	New therapeutic opportunities for women with low-grade serous ovarian cancer. <i>Endocrine-Related Cancer</i> , 2022, 29, R1-R16.	3.1	23
2	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
3	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
4	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
5	Improving Cancer MDT performance in Western Sydney – three years’ experience. <i>BMC Health Services Research</i> , 2021, 21, 203.	2.2	3
6	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. <i>Cancers</i> , 2021, 13, 3196.	3.7	3
7	Developing a maturity model for cancer multidisciplinary teams. <i>International Journal of Medical Informatics</i> , 2021, 156, 104610.	3.3	3
8	Developing an Intranet-Based Lymphedema Dashboard for Breast Cancer Multidisciplinary Teams: Design Research Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e13188.	4.3	13
9	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1306-1315.	10.7	87
10	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
11	Attitudes of health professionals to using routinely collected clinical data for performance feedback and personalised professional development. <i>Medical Journal of Australia</i> , 2019, 210, S17-S21.	1.7	19
12	A tool to improve the performance of multidisciplinary teams in cancer care. <i>BMJ Open Quality</i> , 2019, 8, e000435.	1.1	11
13	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
14	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 1508.	3.3	3
15	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 680-688.	2.5	2
16	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
17	<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. <i>JCO Precision Oncology</i> , 2018, 2, 1-14.	3.0	19
18	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. <i>Gynecologic Oncology</i> , 2018, 150, 239-246.	1.4	32

#	ARTICLE	IF	CITATIONS
19	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
20	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. <i>Journal of Circulating Biomarkers</i> , 2018, 7, 184945441878261.	1.3	47
21	Multidisciplinary teams and ICT: a qualitative study exploring the use of technology and its impact on multidisciplinary team meetings. <i>BMC Health Services Research</i> , 2018, 18, 444.	2.2	30
22	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 48-48.	1.6	12
23	Our Faustian pact with the digital world. <i>Lancet Oncology</i> , The, 2017, 18, 171-172.	10.7	0
24	Dose-Response Association of CD8 <sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
25	Embedding continuous quality improvement processes in multidisciplinary teams in cancer care: exploring the boundaries between quality and implementation science. <i>Australian Health Review</i> , 2017, 41, 291.	1.1	18
26	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017, 77, 4268-4278.	0.9	56
27	A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 63-72.	2.5	35
28	Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. <i>PLoS ONE</i> , 2017, 12, e0175544.	2.5	64
29	Carboplatin allergy and IgE regulation. <i>Pathology</i> , 2016, 48, S48.	0.6	0
30	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. <i>Gynecologic Oncology</i> , 2016, 142, 458-464.	1.4	17
31	Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982â€“2011. <i>Cancer Epidemiology</i> , 2016, 43, 15-21.	1.9	12
32	A mixed methods approach to developing and evaluating oncology trainee education around minimization of adverse events and improved patient quality and safety. <i>BMC Medical Education</i> , 2016, 16, 91.	2.4	11
33	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
34	An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. <i>JMIR Research Protocols</i> , 2016, 5, e147.	1.0	5
35	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	27.8	1,206
36	Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. <i>Oncogene</i> , 2015, 34, 485-495.	5.9	38

#	ARTICLE	IF	CITATIONS
37	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver. <i>Clinical Cancer Research</i> , 2014, 20, 6618-6630.	7.0	96
38	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	107
39	Retrospective imaging audit and cost analysis of medical oncology inpatients admitted to Westmead Hospital. <i>Internal Medicine Journal</i> , 2014, 44, 1235-1239.	0.8	3
40	Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. <i>Annals of Oncology</i> , 2014, 25, 160-165.	1.2	25
41	Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 105-106.	3.8	19
42	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. <i>Scientific Reports</i> , 2014, 4, 4669.	3.3	24
43	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5563-5563.	1.6	0
44	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	4.4	25
45	Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. <i>European Journal of Cancer</i> , 2013, 49, 3396-3403.	2.8	54
46	Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 228-234.	1.2	61
47	NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. <i>ISRN Hepatology</i> , 2013, 2013, 1-7.	0.9	1
48	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. <i>Cancer Research</i> , 2012, 72, 4060-4073.	0.9	100
49	All pains are equal, but some seem more urgent than others. <i>Lancet, The</i> , 2012, 380, 28.	13.7	0
50	Choriocarcinoma of the lung masquerading as a persisting pregnancy of unknown location (PUL). <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2012, 52, 211-212.	1.0	3
51	Beyond evidence: reappraising use of CA125 as posttherapy surveillance for ovarian cancer. <i>Medical Journal of Australia</i> , 2012, 196, 440-441.	1.7	0
52	The perils of a vanishing cohort: a study of social comparisons by women with advanced ovarian cancer. <i>Psycho-Oncology</i> , 2012, 21, 382-391.	2.3	3
53	Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. <i>European Journal of Echocardiography</i> , 2011, 12, 945-952.	2.3	135
54	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47

#	ARTICLE	IF	CITATIONS
55	Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS ONE, 2011, 6, e17617.	2.5	36
56	Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Social Science and Medicine, 2010, 71, 1548-1556.	3.8	12
57	Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 66-73.	1.1	6
58	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	7.0	266
59	New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents. Critical Reviews in Oncology/Hematology, 2008, 67, 103-112.	4.4	69
60	<i>ABCB1</i> ( <i>MDR 1</i> ) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	7.0	90
61	Ankyrin Repeat Domain 1, <i>ANKRD1</i> , a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 2008, 14, 6924-6932.	7.0	33
62	CARBOPLATIN DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2007, 99, 468-469.	1.0	2
63	Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. International Journal of Gynecological Cancer, 2007, 17, 359-366.	2.5	17
64	Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 2007, 17, 350-358.	2.5	11
65	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 2006, 100, 239-246.	1.4	58
66	Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 2005, 117, 1049-1054.	5.1	78
67	Managing quality in cancer services: why improvement isn't easy. Australian Health Review, 2005, 29, 406.	1.1	2
68	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecologic Oncology, 2004, 93, 417-421.	1.4	23
69	Carboplatin desensitization. Annals of Allergy, Asthma and Immunology, 2004, 93, 137-141.	1.0	33
70	Expression of Progesterone Receptor A and B Isoforms in Low-grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 2004, 23, 138-144.	1.4	50
71	"But Doctor, What Have I Got to Lose . . . ?". Journal of Clinical Oncology, 2003, 21, 27s-29.	1.6	8
72	Scientists and clinicians test their metalâ€“back to the future with platinum compounds. Lancet Oncology, The, 2002, 3, 312-318.	10.7	26

#	ARTICLE	IF	CITATIONS
73	A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. <i>Medical Journal of Australia</i> , 2001, 174, 312-312.	1.7	16
74	“But Doctor, What Have I Got to Lose . . . ?” <i>Journal of Clinical Oncology</i> , 2001, 19, 3294-3296.	1.6	12
75	I now wear a white coat. <i>Medical Journal of Australia</i> , 2001, 175, 228-228.	1.7	0
76	Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 229-234.	2.3	38
77	Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy. <i>International Journal of Health Services</i> , 2000, 30, 557-579.	2.5	49
78	Adjuvant chemotherapy for node-positive breast cancer: a retrospective comparison of two different regimens of cyclophosphamide, methotrexate and 5-fluorouracil. <i>Breast</i> , 1999, 8, 28-34.	2.2	2
79	Integrated Multimodality Therapy for Embryonal Rhabdomyosarcoma of the Lower Genital Tract in Postpubertal Females. <i>Gynecologic Oncology</i> , 1998, 70, 141-146.	1.4	10
80	Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and incisional vincristine, ifosfamide and epirubicin. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 400-402.	0.5	8
81	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. <i>Mutation Research DNA Repair</i> , 1998, 407, 243-252.	3.7	4
82	A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. <i>Annals of Oncology</i> , 1998, 9, 1343-1345.	1.2	121
83	A comparison of two Quality-of-Life Questionnaires for cancer clinical trials: The Functional Living Index-Cancer (FLIC) and the Quality of Life Questionnaire Core module (QLQ-C30). <i>Journal of Clinical Epidemiology</i> , 1996, 49, 21-29.	5.0	44
84	Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. <i>European Journal of Cancer</i> , 1996, 32, 2357-2359.	2.8	9
85	PRIMARY PERITONEAL CARCINOMA: A TREATABLE SUBSET OF PATIENTS WITH ADENOCARCINOMA OF UNKNOWN PRIMARY. <i>ANZ Journal of Surgery</i> , 1996, 66, 124-125.	0.7	8
86	Adenocarcinoma of the Duodenum With Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 305-306.	1.3	8
87	Persisting elevation of alphafetoprotein after chemotherapy for germ cell tumour “not always due to viable malignancy?”. <i>European Journal of Cancer</i> , 1995, 31, 1722.	2.8	0
88	Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. <i>European Journal of Cancer</i> , 1995, 31, 1773-1777.	2.8	5
89	Repair of cisplatin-DNA adducts by protein extracts from human ovarian carcinoma. <i>International Journal of Cancer</i> , 1994, 59, 388-393.	5.1	24
90	Heterogeneous repair of platinum-DNA adducts by protein extracts from mammalian tissues. <i>Biochemical Pharmacology</i> , 1994, 48, 1662-1665.	4.4	5

#	ARTICLE	IF	CITATIONS
91	Vertebral osteomyelitis in advanced breast cancer. Australian and New Zealand Journal of Medicine, 1993, 23, 406-406.	0.5	1
92	A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 1993, 158, 319-322.	1.7	37
93	A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 1993, 158, 866-866.	1.7	0
94	Loss of allelic heterozygosity on distal chromosome 1p in Merkel cell carcinoma. Cancer Genetics and Cytogenetics, 1991, 54, 109-113.	1.0	52
95	Demonstration of somatic rearrangements and genomic heterogeneity in human ovarian cancer by DNA fingerprinting. British Journal of Cancer, 1990, 62, 23-27.	6.4	26
96	Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 4614-4618.	7.1	202
97	Cisplatin plus VP16-213 in advanced ovarian carcinoma. Gynecologic Oncology, 1988, 30, 159-162.	1.4	2
98	Drug resistance in clinical practice: Patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 1601-1605.	0.7	5
99	Aminoglutethimide in Advanced Prostatic Carcinoma. British Journal of Urology, 1987, 59, 323-327.	0.1	21
100	Orbital Metastasis from Prostatic Carcinoma. British Journal of Urology, 1987, 59, 591-592.	0.1	5